Landos Biopharma, Inc. announced that it will present additional findings from its Phase 1b study of NX-13 for the treatment of ulcerative colitis (UC), including detailed results on the rapid symptomatic relief and improvement in multiple clinical biomarkers observed in the study, at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting, being held October 20-25 in Vancouver, Canada. The Company continues to actively recruit, screen and randomize patients for the NEXUS trial, with topline results expected by the fourth quarter of 2024. Presentation Details: Title: The Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 (NLRX1) Agonist NX-13 Demonstrates Rapid Symptomatic and Biomarkers Improvement in Ulcerative Colitis: Results In a Phase 1b Study (00997) Scientific Poster Session: P3607 Date & Time: Tuesday, October 24, 2023 at 10:30am - 4:00pm PDT Title: Rapid Symptomatic Relief Is Correlated with Early Endoscopic Response to the Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 (NLRX1) Agonist NX-13 In Ulcerative Colitis: Results in a Phase 1b Study (00995) Scientific Poster Session: P3644 Date & Time: Tuesday, October 24, 2023 at 10:30am - 4:00pm PDT Title: Target Engagement and Pharmacodynamic Molecular Mechanism Evaluation In A Phase 1b Study of The Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 (NLRX1) Agonist NX-13 in Ulcerative Colitis (00958) Scientific Poster Session: P3548 Date & Time: Tuesday, October 24, 2023 at 10:30am - 4:00pm PDT.